PT - JOURNAL ARTICLE AU - Monika Bratová AU - Karolina Hurdalkova AU - Marie Drosslerova AU - Juraj Kultan AU - Matyas Wanke AU - Martin Svaton AU - Kristian Brat TI - Lung Cancer vs. „Young Cancer“ – Is There a Difference? AID - 10.1183/13993003.congress-2021.PA3851 DP - 2021 Sep 05 TA - European Respiratory Journal PG - PA3851 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/PA3851.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/PA3851.full SO - Eur Respir J2021 Sep 05; 58 AB - Introduction: Lung cancer is the leading cause of death among all cancer diseases worldwide. Most of patients were in the age group of 65-69 years, however we also experience young patients with lung cancer. This subgroup is rather small, but it deserves major attention.Aims: Our study focused on patients aged under 40 years with lung cancer diagnosed between 2011-18 in five pneumo-oncology centers in Czechia. Our aim was to analyze demographic and tumor characteristics, treatment and survival outcomes contraty to the older patients (cohort 2).Methods: Basic characteristics were described by standard descriptive statistics. Chi-squared test and Fisher exact test were used for comparison of variables between cohorts. Kaplan-Meier survival analysis was used to estimate PFS and OS. As a level of statistical significance, p value <0.05 was used.Results: We found 66 patients under 40ty with lung cancer – 61 patients with NSCLC and 5 patients with SCLC, only NSCLC patients were underwent to a further analysis (cohort 1). This cohort counts 50, 8% of men, mean age 34,6 years, 54,1% of non-smokers (vs 79,7% in cohort 2, p <0.001), mainly in a good performance status. About 82% were in IV stage (vs 67,7%, p<0.001). Adenocarcinomas dominated (75,4%), 16,3% were EGFR positive (vs 21,6% in cohort 2), 25,6% ALK positive (vs 8,5% in cohort 2). Median PFS of young lung cancer patients was 3,7 months (vs 4,9 months, p = 0,006), OS reached 11,7 months (vs 22,3 months, p <0.001).Conclusions: Patients under 40ty have much worse prognosis than older patients with lung cancer. The investigation of a different etiopathogenesis of their disease is needed as well as a new approach both in diagnosis and treatment.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3851.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).